The Lancet
Study
Jun 2022
Patients and professionals
One of the first 'head-to-head' trials comparing two biologics directly, in people who had never had a biologic. At one year, about 65% on ustekinumab and 61% on adalimumab were in remission, a difference too small to matter. Both worked well, so the choice between them can depend on other things such as preference and how the drug is given.
Topics
Biologics and newer medicines
Research
Jargon explained
head-to-head trial
biologic-naive
confidence interval
New England Journal of Medicine
Study
Jul 2024
Patients and professionals
A head-to-head trial in people whose Crohn's had not responded to, or who could not tolerate, anti-TNF drugs. Risankizumab (Skyrizi) was at least as good as ustekinumab (Stelara) for remission at 24 weeks and better at healing the bowel lining by 48 weeks. Side effects looked similar.
Topics
Biologics and newer medicines
Research
Jargon explained
non-inferiority
endoscopic remission
anti-TNF
Cochrane
Systematic review
Jun 2026
Patients and professionals
An NIHR-funded Cochrane review that compares all the biologic and newer drugs for Crohn's at once, even where they were never tested against each other directly. Many, including adalimumab, risankizumab, guselkumab, upadacitinib and vedolizumab, were probably or possibly better than placebo, but the strength of evidence varied a lot. The authors say more head-to-head trials, more focus on bowel healing, and better long-term safety data are needed.
Topics
Biologics and newer medicines
Research
Jargon explained
network meta-analysis
relative risk
number needed to treat
biosimilar
NHS
Web page
Dec 2022
For patients
The NHS explains what a clinical trial is and how to find one. It suggests asking your doctor or a patient organisation, and points to the Be Part of Research website, where you can search UK studies and contact researchers.
Topics
Research
Jargon explained
clinical trial
randomised
Crohn's & Colitis UK
Web page
Jul 2026
For patients
Explains how new IBD medicines move from lab testing through clinical trials to licensing, and describes medicines currently in late-stage testing.
Topics
Research
Medicines
Jargon explained
clinical trial
licensing
phase 3
US National Library of Medicine
Tool
Patients and professionals
The largest worldwide database of clinical studies, run by the US government. It includes many trials running at UK hospitals, often drug-company trials of new Crohn's medicines. Each record lists the study's aim, who can join and where.
Topics
Research
Jargon explained
clinical trial
eligibility criteria
trial registry
NCT number
Cochrane
Systematic review
Jul 2023
Patients and professionals
Pooling several trials, Cochrane found high-certainty evidence that vedolizumab (Entyvio) works better than placebo both for bringing on remission and keeping it. Overall side effects were probably similar to placebo. Head-to-head comparisons with other biologics are still needed.
Topics
Biologics and newer medicines
Research
Jargon explained
high-certainty evidence
induction
maintenance
integrin
The Lancet
Study
Dec 2017
Patients and professionals
CALM compared deciding treatment on symptoms alone with 'tight control', where treatment was stepped up if blood or poo tests (CRP and faecal calprotectin) showed inflammation even when people felt fine. After 48 weeks, 46% in the tight control group had a healed bowel lining compared with 30% in the symptom-only group. It is a cornerstone of the 'treat to target' approach.
Topics
Monitoring
Biologics and newer medicines
Research
Jargon explained
tight control
faecal calprotectin
CRP
mucosal healing
treat to target
NIHR
Tool
For patients
The NHS research service's search tool for finding health studies to take part in across the UK. Searching for Crohn's disease lists studies currently recruiting, with who can join and where. A good first stop if you want to volunteer for a trial.
Topics
Research
Jargon explained
clinical trial
recruiting
The Lancet
Study
May 2022
Patients and professionals
Two trials testing risankizumab (Skyrizi) drips to bring active Crohn's under control, including in people for whom other biologics had failed. Risankizumab led to more remissions, and more improvement seen on camera tests of the bowel, at 12 weeks than placebo, and was generally well tolerated.
Topics
Biologics and newer medicines
Jargon explained
induction
phase 3 trial
endoscopic response
The Lancet Gastroenterology & Hepatology
Study
May 2024
Patients and professionals
A large UK-led trial of 386 newly diagnosed adults. Starting straight away with infliximab plus an immunosuppressant ('top-down') kept 79% in remission without steroids or surgery for a year, compared with 15% using the usual 'step-up' approach of trying milder drugs first. There were also fewer flares, serious side effects and operations. A blood test meant to predict who needed strong treatment did not help. Free to read in full.
Topics
Biologics and newer medicines
Research
About Crohn's disease
Jargon explained
top-down treatment
step-up treatment
biomarker
steroid-free remission
top-down
step-up
immunomodulator
randomised controlled trial
New England Journal of Medicine
Study
Apr 2010
Patients and professionals
A landmark trial of 508 adults with moderate to severe Crohn's who had never had immunosuppressants or biologics. Infliximab and azathioprine together worked best: about 57% were in remission without steroids at 26 weeks, against 44% on infliximab alone and 30% on azathioprine alone. This is why many people starting infliximab are offered a second 'helper' drug alongside it.
Topics
Biologics and newer medicines
Immunosuppressants
Research
Jargon explained
combination therapy
steroid-free remission
mucosal healing
randomised controlled trial